| Literature DB >> 21292720 |
Amirta Benning1, Mary Dixon-Woods, Ugochi Nwulu, Maisoon Ghaleb, Jeremy Dawson, Nick Barber, Bryony Dean Franklin, Alan Girling, Karla Hemming, Martin Carmalt, Gavin Rudge, Thirumalai Naicker, Amit Kotecha, M Clare Derrington, Richard Lilford.
Abstract
OBJECTIVE: To independently evaluate the impact of the second phase of the Health Foundation's Safer Patients Initiative (SPI2) on a range of patient safety measures. Design A controlled before and after design. Five substudies: survey of staff attitudes; review of case notes from high risk (respiratory) patients in medical wards; review of case notes from surgical patients; indirect evaluation of hand hygiene by measuring hospital use of handwashing materials; measurement of outcomes (adverse events, mortality among high risk patients admitted to medical wards, patients' satisfaction, mortality in intensive care, rates of hospital acquired infection). Setting NHS hospitals in England. PARTICIPANTS: Nine hospitals participating in SPI2 and nine matched control hospitals. INTERVENTION: The SPI2 intervention was similar to the SPI1, with somewhat modified goals, a slightly longer intervention period, and a smaller budget per hospital.Entities:
Mesh:
Year: 2011 PMID: 21292720 PMCID: PMC3033437 DOI: 10.1136/bmj.d199
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Summary of substudies in evaluation of phase two of Safer Patients Initiative (SPI2)
| Substudy and topic | Data source | Unit of analysis |
|---|---|---|
| Staff survey* | ||
| Staff morale, culture, and opinion | NHS national staff survey | Staff member |
| In patients aged >65 with acute respiratory disease | Case note reviews (both explicit and implicit) | Patient |
| In patients with total hip replacement and open colectomy | Explicit case note review | Patient |
| Use of consumables for hand hygiene | National observation study of effectiveness of national “cleanyourhands” campaign | Hospital |
| Adverse events in patients aged >65 with acute respiratory disease* | Holistic case note review | Patient |
| Hospital mortality in patients aged >65 with acute respiratory disease* | Case note review | Patient |
| Intensive care unit mortality† | Routine data from intensive care national audit and research centre | Hospital |
| Infection rates associated with healthcare † | Routine data from Health Protection Agency | Hospital |
| Patient satisfaction* | NHS patient surveys | Patient‡ |
*Data collected and analysed centrally
†Data collected by hospital staff, then analysed centrally.
‡In SPI1 unit of analysis was “hospital” as, in that case, we did not have individual patient data.
SPI2 and matched control hospitals in phase two of Safer Patients Initiative (SPI2)
| Hospital No | Beds (hospital, current) | Area* | Teaching status† |
|---|---|---|---|
| 1 | 411 | Rural | Affiliated |
| 2 | 455 | Urban | Nil |
| 3 | 620 | Urban/rural | Nil |
| 4 | 634 | Urban | Nil |
| 5 | 688 | Urban | Teaching hospital |
| 6 | 804 | Urban | Teaching hospital |
| 7 | 668 | Urban | Teaching hospital |
| 8 | 523 | Urban | Teaching hospital |
| 9 | 566 | Urban | Affiliated |
| 1 | 475 | Rural | Nil |
| 2 | 511 | Urban | Nil |
| 3 | 618 | Urban | Teaching hospital |
| 4 | 723 | Urban/rural | Nil |
| 5 | 447 | Urban/rural | Affiliated |
| 6 | 789 | Urban | Affiliated |
| 7 | 988 | Urban | Affiliated |
| 8 | 532 | Urban/rural | Nil |
| 9 | 1036 | Urban | Affiliated |
*Based on visual inspection of population density map.
†According to hospital website.
Staff survey scores in control and SPI2 hospitals at two periods in evaluation of phase two of Safer Patients Initiative (SPI2)
| Survey question† | Control hospitals | SPI2 hospitals | Range at baseline‡ | Effect of SPI2 (99% CI), P value | Point estimate favours SPI2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Survey 1 | Survey 2* | Absolute % change | Survey 1 | Survey 2* | Absolute % change | |||||||||||
| No of responders | Score (SE) | No of responders | Score (SE) | No of responders | Score (SE) | No of responders | Score SE) | |||||||||
| Well structured appraisals within previous 12 months14 15 | 3477 | 28 (1) | 3429 | 28 (1) | −1 | 3783 | 28 (1) | 3734 | 26 (1) | −2 | 20-39 | −3 (−9 to 3), 0.191 | No | |||
| Working in well structured teams16 | 3498 | 36 (1) | 3408 | 37 (1) | 1 | 3781 | 38 (1) | 3747 | 38 (1) | 0 | 32-42 | −4 (−12 to 4), 0.205 | No | |||
| Witnessed potentially harmful errors or near misses in previous month | 3602 | 37 (1) | 3532 | 33 (1) | −4 | 3918 | 41 (1) | 3851 | 40 (1) | −1 | 32-47 | 4 (−3 to 10), 0.167 | No | |||
| Work related injury in previous 12 months | 3524 | 19 (1) | 3490 | 16 (1) | −3 | 3848 | 19 (1) | 3796 | 18 (1) | −1 | 16-23 | 2 (−2 to 5), 0.182 | No | |||
| Work related stress in previous 12 months | 3575 | 33 (1) | 3532 | 27 (1) | −6 | 3882 | 32 (1) | 3842 | 27 (1) | −6 | 26-40 | 1 (−5 to 6), 0.670 | No | |||
| Physical violence from patients/relatives in previous 12 months | 3598 | 11 (1) | 3536 | 11 (1) | −1 | 3884 | 11 (1) | 3849 | 11 (1) | 0 | 7-16 | 1 (−3 to 3), 0.645 | No | |||
| Intention to leave17 | 3557 | 3.26 (0.02) | 3544 | 3.40 (0.02) | 0.14 | 3880 | 3.31 (0.01) | 3865 | 3.42 (0.01) | 0.11 | 3.07-3.50 | −0.04 (−0.12 to 0.04), 0.198 | Yes | |||
| Staff job satisfaction17 | 3593 | 3.34 (0.01) | 3568 | 3.44 (0.01) | 0.10 | 3902 | 3.40 (0.01) | 3898 | 3.49 (0.01) | 0.09 | 3.23-3.50 | −0.02 (−0.08 to 0.04), 0.422 | No | |||
| Quality of work-life balance17 | 3568 | 2.77 (0.02) | 3536 | 2.56 (0.02) | −0.22 | 3868 | 2.68 (0.02) | 3857 | 2.51 (0.02) | −0.17 | 2.46-2.97 | 0.05 (−0.04 to 0.14), 0.142 | Yes | |||
| Support from supervisors17 | 3583 | 3.39 (0.02) | 3551 | 3.56 (0.02) | 0.17 | 3894 | 3.43 (0.01) | 3869 | 3.61 (0.01) | 0.18 | 3.22-3.53 | 0.00 (−0.08 to 0.07), 0.889 | — | |||
| Organisational climate17 18 | 3578 | 2.79 (0.01) | 3551 | 2.87 (0.01) | 0.08 | 3861 | 2.91 (0.01) | 3886 | 2.92 (0.01) | 0.01 | 2.52-3.07 | −0.07 (−0.14 to 0.00), 0.009 | No | |||
| Fairness and effectiveness of incident reporting procedures17§ | 3555 | 3.36 (0.01) | 3487 | 3.41 (0.01) | 0.05 | 3861 | 3.41 (0.01) | 3803 | 3.45 (0.01) | 0.04 | 3.27-3.54 | −0.01 (−0.05 to 0.04), 0.664 | No | |||
| Availability of hand washing materials17§ | 2939 | 4.58 (0.01) | 3126 | 4.75 (0.01) | 0.17 | 3231 | 4.51 (0.01) | 3418 | 4.67 (0.01) | 0.16 | 4.32-4.72 | −0.01 (−0.07 to 0.04), 0.587 | No | |||
*After intervention.
†First six scores are percentages, simply reflecting percentage of respondents who answered “yes” to single question or set of questions. The seven others are on scale of 1-5 and are based on mean of between three and six questions, each of which was scored between 1 and 5 for each respondent. For six of these seven scores, higher scores are better, though for “intention to leave” lower scores are better.
‡Indicates range of scores across intervention and control hospitals in first survey to give some context for level of change shown. Difference in change and corresponding confidence interval does not necessarily reflect difference in absolute change because of inclusion of covariates in models tested.
§These scores were not included in SPI1 evaluation.
Medical history taking (% of patients asked required questions) before (epoch 1) and after (epoch 2) phase two of Safer Patients Initiative (SPI2) and effect of SPI. Figures are percentages (binomial standard errors (SE)) and odds ratios (99% confidence intervals) and P values for effect of SPI2
| Control hospitals | SPI2 hospitals | OR (99% CI)†, P value | ||||||
|---|---|---|---|---|---|---|---|---|
| Epoch 1 (n=120) | Epoch 2 (n=123) | Epoch 3* (n=112) | Epoch 1 (n=116) | Epoch 2 (n=117) | Epoch 3* (n=114) | |||
| Duration of “presenting” symptom | 93 (2) | 91 (3) | 96 (2) | 97 (2) | 98 (1) | 99 (1) | 1.7 (0.07 to 40.3), 0.672 | |
| Normal exercise tolerance | 27 (4) | 32 (4) | 38 (5) | 39 (5) | 38 (5) | 34 (5) | 0.7 (0.3 to 1.7), 0.312 | |
| Presence/absence shortness of breath | 88 (3) | 91 (3) | 88 (3) | 91 (3) | 93 (2) | 92 (3) | 1.3 (0.3 to 5.7), 0.701 | |
| Presence/absence orthopnoea | 23 (4) | 28 (4) | 17 (4) | 33 (4) | 29 (4) | 18 (4) | 0.9 (0.3 to 2.6), 0.749 | |
| Presence/absence cough | 88 (3) | 89 (3) | 87 (3) | 91 (3) | 92 (3) | 84 (4) | 0.7 (0.2 to 2.4), 0.407 | |
| If cough present, was it productive | 78 (4) | 85 (3) | 78 (4) | 87 (3) | 88 (3) | 77 (4) | 0.7 (0.2 to 2.1), 0.418 | |
| Smoking history taken | 74 (4) | 81 (4) | 66 (5) | 78 (4) | 80 (4) | 74 (4) | 1.5 (0.5 to 4.0), 0.313 | |
| Presence/absence of haemoptysis | 22 (4) | 28 (4) | 16 (4) | 25 (4) | 23 (4) | 26 (4) | 2.2 (0.7 to 6.5), 0.061 | |
| Chest pain (of any type) | 68 (4) | 72 (4) | 55 (5) | 54 (5) | 66 (4) | 60 (5) | 2.1 (0.9 to 5.2), 0.028 | |
| Occupation/previous occupation | 44 (5) | 38 (4) | 54 (5) | 35 (5) | 39 (5) | 38 (5) | 0.6 (0.3 to 1.5), 0.178 | |
| Pets at home | 3 (2) | 3 (2) | 1 (1) | 2 (1) | 3 (2) | 6 (2) | 8.3 (0.3 to 210.0), 0.093 | |
| % over all items | 56 | 58 | 54 | 68 | 59 | 57 | — | |
*After intervention.
†OR >1 favours SPI2.
Vital signs in phase two of Safer Patients Initiative (SPI2). Figures are percentage compliance with standards with standard errors (SE) and odds ratios for changes over time and effect of SPI2
| Control hospitals | SPI2 hospitals | OR (99% CI)†, P value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Epoch 1 (n=120) | Epoch 2 (n=123) | Epoch 3* (n=112) | Epoch 1 (n=116) | Epoch 2 (n=117) | Epoch 3* (n=114) | Changes in controls | Effect of SPI2 | |||
| Temperature | 97 (2) | 99 (1) | 99 (1) | 99 (1) | 99 (1) | 97 (2) | 0.7 (0.02 to 24.0), 0.823 | 0.1 (0.002 to 4.1), 0.108 | ||
| Respiratory rate | 96 (2) | 99 (1) | 100 | 97 (2) | 98 (1) | 100 | NA | NA | ||
| Cyanosis/oxygen saturation | 98 (1) | 98 (1) | 100 | 99 (1) | 99 (1) | 100 | NA | NA | ||
| Confusion/mental state | 53 (5) | 72 (4) | 74 (4.2) | 63 (5) | 57 (5) | 81 (4) | 1.8 (0.8 to 3.7), 0.045 | 1.7 (0.6 to 4.5), 0.187 | ||
| Pulse | 98 (1) | 99 (1) | 100 | 99 (1) | 99 (1) | 100 | NA | NA | ||
| Blood pressure | 98 (1) | 99 (1) | 100 | 99 (1) | 99 (1) | 100 | NA | NA | ||
| Temperature | 62 (5) | 70 (4) | 70 (4) | 63 (5) | 78 (4) | 68 (4) | 1.4 (0.7 to 2.8), 0.239 | 0.8 (0.3 to 1.9), 0.457 | ||
| Respiratory rate | 41 (5) | 69 (4) | 72 (4) | 47 (5) | 76 (4) | 78 (4) | 2.1 (1.0 to 4.3), 0.010 | 1.0 (0.4 to 2.8), 0.907 | ||
| Pulses | 69 (4) | 73 (4) | 75 (4) | 65 (5) | 81 (4) | 80 (4) | 1.3 (0.6 to 2.8), 0.327 | 1.2 (0.4 to 3.3), 0.662 | ||
| Oxygen saturation | 62 (5) | 72 (4) | 74 (4) | 61 (5) | 79 (4) | 80 (4) | 1.4 (0.7 to 3.0), 0.223 | 1.2 (0.4 to 3.1), 0.703 | ||
| Temperature | 58 (5) | 71 (4) | 69 (4) | 59 (5) | 70 (4) | 73 (4) | 1.2 (0.6 to 2.4), 0.583 | 1.2 (0.5 to 2.9), 0.685 | ||
| Respiratory rate | 35 (4) | 70 (4) | 73 (4) | 45 (5) | 68 (4) | 79 (4) | 2.4 (1.1 to 5.0), 0.002 | 1.2 (0.4 to 3.1), 0.713 | ||
| Pulse | 63 (4) | 76 (4) | 75 (4) | 60 (5) | 71 (4) | 80 (4) | 1.2 (0.6 to 2.5), 0.510 | 1.5 (0.6 to 4.1), 0.268 | ||
| Oxygen saturation | 54 (5) | 76 (4) | 74 (4) | 57 (5) | 71 (4) | 80 (4) | 1.4 (0.7 to 2.9), 0.231 | 1.4 (0.5 to 3.6), 0.430 | ||
| Urea and electrolytes | 99 (1) | 98 (1) | 99 (1) | 100 | 99 (1) | 100 | 0.6 (0.01 to 27.7), 0.762 | NA | ||
| Chest x ray | 97 (2) | 98 (1) | 97 (2) | 97 (2) | 98 (1) | 100 | 0.7 (0.1 to 5.6), 0.641 | NA | ||
| Full blood count | 98 (1) | 98 (1) | 99 (1) | 99 (1) | 99 (1) | 100 | 1.7 (0.1 to 40.4), 0.663 | NA | ||
NA=not applicable because of 100% in cells.
*After intervention.
†OR >1 favours SPI2. No items showed significant variation between hospitals within arms.
Use of systemic steroids, CURB score, and other standards applicable to specific cases—compliance with standards in phase two of Safer Patients Initiative (SPI2). Figures are numbers (percentage, SE) and odds ratios (99% confidence interval) and P values for effect of SPI2
| Standard | Control hospitals | SPI2 hospitals | Effect of SPI2† | |||||
|---|---|---|---|---|---|---|---|---|
| Epoch 1 | Epoch 2 | Epoch 3* | Epoch 1 | Epoch 2 | Epoch 3* | |||
| Asthma or COPD: steroids given within 24 hours | 70 (84, 4) | 63 (92, 4) | 56 (93, 4) | 59 (92, 4) | 74 (93, 3) | 53 (94, 3) | 0.6 (0.05 to 6.8), 0.568 | |
| Asthma: peak flow recorded | 10 (80, 13) | 11 (64, 15) | 5 (40, 22) | 24 (79, 8) | 18 (94, 5) | 8 7 (5, 15) | 29.7 (0.1 to 16000), 0.165 | |
| Community acquired pneumonia: CURB score recorded | 52 (2, 2) | 67 (22, 5) | 56 (21, 6) | 50 (2, 2) | 44 (25, 6) | 60 (42, 6) | 2.1 (0.4 to 11.1), 0.236 | |
COPD=chronic obstructive pulmonary disease; CURB=confusion/urea/respiratory rate/blood pressure score.
*After intervention.
†OR >1 favours SPI2. No items showed significant variation between hospitals within arms.
Analysis of prescribing errors before (epoch 1) and after (epoch 3) phase two of Safer Patients Initiative (SPI2)*
| Control hospitals | SPI2 hospitals | ||||||
|---|---|---|---|---|---|---|---|
| Epoch 1 | Epoch 2 | Epoch 3† | Epoch 1 | Epoch 2 | Epoch 3† | ||
| No of patients‡ | 120 | 122 | 112 | 113 | 117 | 114 | |
| No of prescriptions | 2953 | 3269 | 2871 | 2529 | 2938 | 2656 | |
| Prescriptions per patient | 24.6 | 26.8 | 25.6 | 22.4 | 25.1 | 23.3 | |
| No of errors | 345 | 298 | 216 | 251 | 266 | 167 | |
| Error rate (SE) per prescription | 0.12 (0.02) | 0.09 (0.01) | 0.08 (0.01) | 0.101(0.02) | 0.09 (0.01) | 0.06 (0.01) | |
*Breakdown of error types, including failure to reconcile patient’s previous medicines with prescription on admission (particular focus of SPI), available in full report (www.haps.bham.ac.uk/publichealth/psrp/EvalSPI.shtml).2
†After intervention.
‡With medication charts available for review.
Rates of compliance with perioperative care standards before (epoch 2) and after (epoch 3) phase two of Safer Patients Initiative (SPI2). Figures are percentages (standard error (SE)) and odds ratios and P values for effect of SPI2
| Control hospitals | SPI2 hospitals | OR (99% CI)*, P value | ||||
|---|---|---|---|---|---|---|
| Before intervention (n=51) | After intervention (n=43) | Before intervention (n=79) | After intervention (n=69) | |||
| “Advanced method” of pain relief† | 94 (4) | 95 (4) | 85 (4) | 83 (5) | 0.8 (0.03 to 18.4), 0.820 | |
| Perioperative antibiotic given | 94 (3) | 100 | 98 (2) | 97 (2) | NA | |
| Temperature monitored‡ | 16 (5) | 30 (7) | 29 (5) | 41 (6) | 0.9 (0.1 to 5.2), 0.854 | |
| Appropriate DVT prophylaxis§ | 100 | 100 | 99 (1) | 100 | NA | |
DVT=deep vein thrombosis; NA=not applicable because of 100% in cells.
*OR >1 favours SPI2.
†Hospital staff identified 15 cases with contraindications to this standard, all of which were corroborated by reviewers. Data relate to 227 patients who were eligible.
‡ Evidence of heterogeneity between hospitals at baseline.
§ Three patients had contraindications yielding denominator of 238. Withheld in only two patients with no contraindications but wrongly administered in two patients with contraindication.

Fig 1 Rates of consumption of soap over time in control and SPI2 hospitals

Fig 2 Rates of consumption of alcohol hand rub over time in control and SPI2 hospitals
Mortality among acute medical care patients whose case notes were explicitly reviewed before (epoch 1) and after (epoch 3) phase 2 of Safer Patients Initiative (SPI2)
| Control hospitals | SPI2 hospitals | ||||||
|---|---|---|---|---|---|---|---|
| Epoch 1 | Epoch 2 | Epoch 3* | Epoch 1 | Epoch 2 | Epoch 3* | ||
| No of patients | 120 | 123 | 112 | 116 | 117 | 114 | |
| Deaths | 18 | 24 | 24 | 9 | 15 | 7 | |
| % mortality (SE) | 15 (3.3) | 20 (3.6) | 21 (3.9) | 8 (2.5) | 13 (3.1) | 6 (2.3) | |
| Mean (SD) age (years) | 77.6 (7.7) | 81.1 (7.9) | 79.6 (8.0) | 77.7 (7.6) | 78.1 (7.1) | 80.6 (7.8) | |
| % women | 63.3 | 53.7 | 53.6 | 53.4 | 50.4 | 52.6 | |
| Mean No of comorbidities | 2.9 | 3.1 | 2.6 | 2.8 | 3.0 | 2.9 | |
*After intervention.
Preventable deaths among acute medical care cases where notes were reviewed holistically across study epochs before (epoch 1) and after (epoch 3) phase two of Safer Patients Initiative (SPI2)
| Epoch | No of deaths (cases reviewed) | Preventable deaths ≥50%* | Preventable deaths <50%† | |||||
|---|---|---|---|---|---|---|---|---|
| 1st reviewer only | 2nd reviewer only | Both reviewers | 1st reviewer only | 2nd reviewer only | Both reviewers | |||
| 1 | 17 (126) | 0 | 0 | 1 | 0 | 0 | 1 | |
| 2 | 24 (126) | 0 | 0 | 1 | 1 | 0 | 1 | |
| 3‡ | 23 (114) | 0 | 0 | 2 | 0 | 1 | 2 | |
| Total | 64 (366) | 0 | 0 | 4 | 1 | 1 | 4 | |
| 1 | 9 (117) | 0 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 11 (120) | 0 | 0 | 1 | 0 | 0 | 1 | |
| 3‡ | 7 (122) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total | 27 (359) | 0 | 0 | 1 | 0 | 0 | 1 | |
*Preventable deaths 50%: on balance of probabilities substandard practice led to death.
†Preventable deaths <50%: substandard practice could have led to death but probability that it did was <50%.
‡After intervention.
Intensive care outcomes in phase two of Safer Patients Initiative (SPI2). Median and interquartile ranges for control and intervention hospitals, before and after intervention period*
| Intensive and critical care outcomes* | Control hospitals | SPI2 hospitals | Difference in difference | |||||
|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | Change (99% CI)† | P value | |||
| Adjusted mortality ratio | 1.14 (0.99-1.32) | 1.24 (1.02-1.33) | 1.04 (0.90-1.15) | 0.97 (0.90-1.15) | 0.09 (−0.11 to 0.29) | 0.25 | ||
| Mean LOS (hours) | 144 (117-174) | 147 (126-185) | 102 (82-130) | 103 (81-137) | 5.86 (−22.78 to 34.50) | 0.60 | ||
| Mean APACHE II score | 20.4 (17.7-22.6) | 19.0 (17.1-20.8) | 21.1 (19.1-23.0) | 20.3 (17.8-21.8) | −0.83 (−3.63 to 1.98) | 0.459 | ||
| Mean ICNARC score | 22.3 (19.5-26.3) | 20.7 (18.0-23.5) | 22.6 (21.2-25.3) | 22.2 (19.7-25.1) | −2.26 (−6.39 to 1.87) | 0.16 | ||
LOS=length of stay; APACHE=acute physiological and chronic health evaluation; ICNARC=Intensive Care National Audit and Research Centre.
*Before period is October 2006 to March 2007 and after period is October 2008 to March 2009.
†Change <1 favours SPI2.

Fig 3 Rates of cases of C difficile per 1000 bed days in control and SPI2 hospitals

Fig 4 Rates of cases of MRSA per 100 000 bed days in control and SPI2 hospitals
Patient survey scores* in control and SPI2 hospitals before (survey 1) and after (survey 2) phase two of Safer Patients Initiative (SPI2)
| Control hospitals | SPI2 hospitals | Range at baseline | Effect of SPI2 (99% CI)†‡, P value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Survey 1 | Survey 2 | Absolute % change | Survey 1 | Survey 2 | Absolute % change | ||||||||||
| No of patients | Score (SE) | No of patients | Score (SE) | No of patients | Score (SE) | No of patients | Score (SE) | ||||||||
| Overall, how would you rate the care you received? | 4200 | 82 (0.4) | 3913 | 85 (0.3) | 4 | 4277 | 80 (0.4) | 3705 | 84 (0.3) | 4 | 75-87 | 1 (−1 to 3), 0.292 | |||
| Overall, did you feel you were treated with respect and dignity while you were in the hospital? | 4111 | 78 (0.4) | 3807 | 82 (0.4) | 4 | 4167 | 76 (0.4) | 3604 | 80 (0.4) | 3 | 65-85 | 0 (−2 to 2), 0.702 | |||
| How would you rate how well the doctors and nurses worked together? | 4182 | 87 (0.4) | 3878 | 88 (0.4) | 1 | 4220 | 88 (0.4) | 3677 | 89 (0.4) | 1 | 83-91 | 0 (−2 to 2), 0.597 | |||
| In your opinion, how clean was the hospital room or ward that you were in? | 4113 | 75 (0.4) | 3870 | 77 (0.4) | 2 | 4201 | 77 (0.4) | 3645 | 78 (0.4) | 1 | 70-80 | −1 (− to 1), 0.141 | |||
| How clean were the toilets and bathrooms that you used in hospital? | 4141 | 76 (0.4) | 3877 | 78 (0.4) | 2 | 4220 | 78 (0.4) | 3665 | 79 (0.4) | 1 | 70-82 | −1 (−3 to 1), 0.204 | |||
*Mean values of five survey scores in control and SPI2 hospitals for first and second patient surveys, rated between 0-100.
†Values >1 favours SPI2.
‡Values differ from simple subtraction because of rounding.
Summary of directions of effects of SPI across all quantitative evaluations of SPI1 and SPI2. Significant results are indicated
| SPI1 | SPI2 | ||||||
|---|---|---|---|---|---|---|---|
| Outcomes favouring SPI | Outcomesfavouring control | Outcomes with no difference | Outcomes favouring SPI | Outcomes favouring control | Outcomes with no difference | ||
| Staff survey | 7* | 3 | 1 | 2 | 10* | 1 | |
| Vital signs | 9* | 3 | 2 | 7 | 2 | 4 | |
| Routine investigation | 0 | 3 | — | — | — | 3 | |
| Specific standards | 0 | 3 | — | 2 | — | — | |
| Prescribing | — | 1 | — | 1 | — | — | |
| Medical history | 5 | 5 | 1 | 6 | 5 | 1 | |
| Mortality among case notes | 1 | — | — | 1 | — | — | |
| Holistic errors | 1 | — | — | — | 1 | — | |
| Holistic adverse events | 1 | — | — | — | 1 | — | |
| Patient survey | 4* | 1 | — | 1 | 2 | 2 | |
| Intensive care mortality | NA | NA | NA | 1 | — | — | |
| Handwashing materials: | |||||||
| Soap | NA | NA | NA | — | 1 | — | |
| Alcohol hand rub | NA | NA | NA | 1 | — | — | |
| NA | NA | NA | 1 | — | — | ||
| MRSA rates | NA | NA | NA | 1 | — | — | |
| Totals | 28 | 19 | 4 | 24 | 22 | 11 | |
NA=Not applicable
*One of these results was significant at P<0.01. Across whole study, four of 108 measured outcomes yielded significant results at P<0.01 when changes in SPI were compared with changes in control. Three of these favoured SPI and one favoured controls. Four further results were significant at P<0.05, but not P<0.01; and all favoured SPI (three in SPI1 and one in SPI2).